Company intelligence / Profile preview

Fe Pharmaceuticals

Redwood City, California, USAfepharm.com ↗

Ownership: Private
Development stage: Preclinical

Overview

DIBI has shown proof-of-concept in various infectious and inflammatory disease models with 27 peer-reviewed publications. It has demonstrated potent, broad-spectrum antimicrobial activity against fungal and bacterial infections, including drug-resistant organisms. In animal models of sepsis, DIBI down-regulated excess cytokine release and promoted survival, acting synergistically with antibiotics.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Iron-binding copolymer
Industry: Biotech

Drug pipeline

3 assets

Topical DIBI

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Fe Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fe Pharmaceuticals.

Explore the full profile